Jasper, a biotech company that has seen most of its market value wiped out, has agreed to be acquired in a merger with Kira, an immune-focused drugmaker, according to BioPharma Dive.
The deal comes bundled with a concurrent licensing agreement involving a startup called Mirador. Together, the arrangement is designed to give Jasper a path forward after a string of setbacks that had battered the company's standing.
BioPharma Dive characterizes the acquisition as a lifeline — a chance for Jasper to rebound after losing nearly all of its market value. In practice, mergers like this often let a struggling company preserve some value for shareholders and keep its scientific programs alive rather than winding down entirely.
For Kira, an immune drugmaker, folding in Jasper alongside the Mirador licensing deal appears aimed at broadening its pipeline. The specifics of the setbacks that hurt Jasper, and the financial terms of the transaction, were framed by BioPharma Dive around the company's dramatic loss of market value.
Why it matters: The deal is a reminder of how quickly fortunes can turn in biotech, where a company that has lost most of its worth can still find a second life through a well-timed merger rather than disappearing outright.